TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 0.200nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 0.480nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 0.480nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 0.510nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 0.510nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 0.520nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 0.520nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 0.650nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 0.650nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 1nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 1.20nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Biotie Therapies
Curated by ChEMBL
Biotie Therapies
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of human recombinant PDE10A expressed in baculovirus-SF21 cell system assessed as hydrolysis of [3H]cAMP after 1 hr by liquid scintillatio...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Biotie Therapies
Curated by ChEMBL
Biotie Therapies
Curated by ChEMBL
Affinity DataIC50: 1.40nMAssay Description:Inhibition of human recombinant PDE10A expressed in baculovirus-SF21 cell system assessed as hydrolysis of [3H]cAMP after 1 hr by liquid scintillatio...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 1.60nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 1.60nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 1.64nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 1.64nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 1.84nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 1.84nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 1.90nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 1.90nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 2.13nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 2.13nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 2.26nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 2.26nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 2.43nMAssay Description:Cells were split 2-3 times weekly between 1:3 and 1:4. For binding assays and membrane preparations the cell culture medium was removed, cells were w...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
TargetGlutamate receptor ionotropic, NMDA 2B(Rattus norvegicus (Rat))
Janssen Pharmaceuticals
US Patent
Janssen Pharmaceuticals
US Patent
Affinity DataIC50: 2.43nMAssay Description:Male Wistar rats (180 to 200 g) were killed by suffocation in a CO2 chamber for two minutes. Whole brains without cerebellum were removed and dissect...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Biotie Therapies
Curated by ChEMBL
Biotie Therapies
Curated by ChEMBL
Affinity DataIC50: 2.80nMAssay Description:Inhibition of human recombinant PDE10A expressed in baculovirus-SF21 cell system assessed as hydrolysis of [3H]cAMP after 1 hr by liquid scintillatio...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 3nMAssay Description:The inhibition of PDE 2A or 10 enzyme activity was assessed using IMAP-Phosphodiesterase-cAMP fluorescence labeled substrate (Molecular Devices, Orde...More data for this Ligand-Target Pair